Adaptive Biotechnologies

Adaptive Biotechnologies develops clinical products for detection and treatment of disease in partnership with Microsoft using an immune medicine platform and machine learning capabilities. The company aims to map population-wide adaptive immune responses in an immunomics database that can enable earlier detection of disease through immune response signatures. Immune response signatures can also be used to design therapeutics.

ImmunoSeq technology is used to sequence the genetic code of T cell receptors and B cell receptors and map them to the antigens they bind to using Mira technology. This shows which diseases a patient’s immune system has been exposed to or is actively fighting. The data linking T cell receptors and antigens is analysed with Microsoft machine learning tools to create a map of antigens and receptors, an immunomics database. Applications include diagnostic testing and therapeutics. Adaptive biotechnologies has a system called PairSeq for reconstructing both chains of the Y shaped receptor for therapeutic purposes. TruTCR is an analytical process to determine optimal candidates for TCR-mediated T-cell therapies.

Adaptive Biotechnologies is applying their technology in partnership with Microsoft to decode the immune response to COVID-19 (SARS-CoV-2 virus) for the purpose of accelerating the development of detection methods and vaccine discovery. Data will be freely available around the world to researchers, public health officials or organizations. Adaptive believes their population level immune response data can be used to help diagnose the virus asymptomatic infected people and improve triaging of newly diagnosed patients and also help find immune response signatures that are relevant to the development of treatments and preventions for COVID-19.